.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 as well as ranked an additional nine labels in the area as overweight. The financial investment bank said in a keep in mind that it continues to feel “diabesity is actually set to come to be.